Literature DB >> 10699616

Clinical characteristics in black and white men with prostate cancer in an equal access medical center.

S J Freedland1, M E Sutter, J Naitoh, F Dorey, G S Csathy, W J Aronson.   

Abstract

OBJECTIVES: To determine whether black men with newly diagnosed prostate cancer in an equal access health care center are more likely to present with metastatic disease, more poorly differentiated tumors, higher serum prostate-specific antigen (PSA) levels, and/or at younger ages compared with white men.
METHODS: A retrospective survey was conducted that identified black and white men with newly diagnosed prostate cancer at the Los Angeles Regional Veterans Affairs Clinics between 1991 and 1997. Patient data were analyzed for racial differences in age at diagnosis, clinical stage, PSA level, and Gleason score of the prostate biopsy specimens.
RESULTS: A total of 477 evaluable patients (230 black, 247 white) with newly diagnosed prostate cancer were identified. No significant differences in the average age (66.9 +/- 7.3 versus 67.9 +/- 7.5) or clinical stage at diagnosis were found between black and white men. Among black men, 87% presented with clinically localized disease (T1-2, Nx, M0) compared with 88% of white men. Only 6% of black men presented with distant disease (Tx, Nx, M1) compared with 4% of white men. Black men had higher median PSA levels than white men (14. 2 versus 9.4 ng/mL, P = 0.0001). Black men also had slightly higher average Gleason scores (6.2 versus 5.9, P = 0.025).
CONCLUSIONS: This is the first study to show a low and equal percentage of black and white men presenting with metastatic prostate cancer. In this equal access center, no differences were found in patient age or clinical stage of prostate cancer between black and white men at the time of diagnosis. However, black men presented with higher serum PSA values and slightly higher Gleason scores.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699616     DOI: 10.1016/s0090-4295(99)00461-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Prostate cancer screening and detection in inner-city and underserved men.

Authors:  Satoshi Anai; John Pendleton; Peter Wludyka; Christopher Williams; Leah Nelms; Curtis Pettaway; Charles J Rosser
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

2.  Systems analysis of the prostate transcriptome in African-American men compared with European-American men.

Authors:  Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli
Journal:  Pharmacogenomics       Date:  2016-06-30       Impact factor: 2.533

Review 3.  One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading.

Authors:  John R Srigley; Brett Delahunt; Lars Egevad; Hemamali Samaratunga; John Yaxley; Andrew J Evans
Journal:  Can Urol Assoc J       Date:  2016 Sep-Oct       Impact factor: 1.862

Review 4.  African-American Prostate Cancer Disparities.

Authors:  Zachary L Smith; Scott E Eggener; Adam B Murphy
Journal:  Curr Urol Rep       Date:  2017-08-14       Impact factor: 3.092

5.  Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.

Authors:  Brandon Bernard; Vinayak Muralidhar; Yu-Hui Chen; Srikala S Sridhar; Edith P Mitchell; Curtis A Pettaway; Michael A Carducci; Paul L Nguyen; Christopher J Sweeney
Journal:  Cancer       Date:  2017-01-05       Impact factor: 6.860

6.  Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer.

Authors:  Charles J Rosser; Deborah A Kuban; Sang-Joon Lee; Lawrence B Levy; Curtis Pettaway; Ashish M Kamat; Ramsey Chichakli; Andrew Lee; Rex M Cheung; Ricardo Sanchez-Ortiz; Louis L Pisters
Journal:  J Natl Med Assoc       Date:  2004-07       Impact factor: 1.798

7.  The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.

Authors:  Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Michael A Carducci; Alan W Partin; Mario A Eisenberger; Patrick C Walsh; Bruce J Trock
Journal:  J Urol       Date:  2007-11-14       Impact factor: 7.450

Review 8.  Biological determinants of health disparities in prostate cancer.

Authors:  Damali N Martin; Adrienne M Starks; Stefan Ambs
Journal:  Curr Opin Oncol       Date:  2013-05       Impact factor: 3.645

Review 9.  'Race' and prostate cancer mortality in equal-access healthcare systems.

Authors:  Tisheeka Graham-Steed; Edward Uchio; Carolyn K Wells; Mihaela Aslan; John Ko; John Concato
Journal:  Am J Med       Date:  2013-12       Impact factor: 4.965

10.  Prostate cancer outcome in Burkina Faso.

Authors:  Fasnéwindé A Kabore; Barnabé Zango; Adama Sanou; Clotaire Yameogo; Brahima Kirakoya
Journal:  Infect Agent Cancer       Date:  2011-09-23       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.